CA2000881A1 - Forme posologique orale d'acides omega-3 polyinsatures - Google Patents

Forme posologique orale d'acides omega-3 polyinsatures

Info

Publication number
CA2000881A1
CA2000881A1 CA 2000881 CA2000881A CA2000881A1 CA 2000881 A1 CA2000881 A1 CA 2000881A1 CA 2000881 CA2000881 CA 2000881 CA 2000881 A CA2000881 A CA 2000881A CA 2000881 A1 CA2000881 A1 CA 2000881A1
Authority
CA
Canada
Prior art keywords
acid
dosage form
enteric dosage
omega
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2000881
Other languages
English (en)
Inventor
Roger A. Pluss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tillotts Pharma AG
Original Assignee
Tillotts Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma AG filed Critical Tillotts Pharma AG
Publication of CA2000881A1 publication Critical patent/CA2000881A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA 2000881 1988-10-21 1989-10-17 Forme posologique orale d'acides omega-3 polyinsatures Abandoned CA2000881A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8824709A GB2223943A (en) 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids
GB8824709.3 1988-10-21

Publications (1)

Publication Number Publication Date
CA2000881A1 true CA2000881A1 (fr) 1990-04-21

Family

ID=10645593

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2000881 Abandoned CA2000881A1 (fr) 1988-10-21 1989-10-17 Forme posologique orale d'acides omega-3 polyinsatures

Country Status (4)

Country Link
AU (1) AU4485689A (fr)
CA (1) CA2000881A1 (fr)
GB (1) GB2223943A (fr)
WO (1) WO1990004391A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906369D0 (en) * 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
FR2663222A1 (fr) * 1990-06-13 1991-12-20 Medgenix Group Sa Microcapsule de liquide huileux.
ZA92452B (en) * 1991-01-24 1992-10-28 Martek Corp Microbial oil mixtures and uses thereof
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
GB2300807B (en) * 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
EP0855908B1 (fr) * 1995-12-11 2002-02-06 Omni Nutraceuticals, Inc. Regime alimentaire a base de complements nutritionnels permettant de soulager les symptomes de l'arthrite
US5840715A (en) * 1995-12-11 1998-11-24 Inholtra Investment Holdings & Trading, N.V. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6797289B2 (en) 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE19930030B4 (de) * 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform
EP1407767A4 (fr) * 2001-06-18 2007-01-24 Yamada Sachiko Preparations medicamenteuses agonistes ppar$g(g)
WO2003043570A2 (fr) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations et procedes destines au traitement ou l'amelioration des etats inflammatoires
NZ539624A (en) * 2002-09-27 2008-08-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
EP1603551A2 (fr) * 2003-03-05 2005-12-14 Solvay Pharmaceuticals GmbH Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
MX2008008171A (es) 2005-12-21 2008-11-12 Brudy Technology S L Uso de dha epa o epa derivado de dha para tratamiento de una patologia asociada al daño celular oxidante.
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
EP4137128A1 (fr) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Composition pharmaceutique contenant de l'acide eicosapentaénoïque et leurs procédés d'utilisation
AU2009334476B2 (en) * 2008-12-31 2013-08-29 Nitromega Corp. Nutraceuticals containing nitro fatty acids
PT2395991E (pt) 2009-02-10 2013-09-03 Amarin Pharmaceuticals Ie Ltd Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia
EP3791880A1 (fr) 2009-04-29 2021-03-17 Amarin Pharmaceuticals Ireland Limited Compositions pharmaceutiques comprenant de l'epa
LT3278665T (lt) 2009-04-29 2020-12-10 Amarin Pharmaceuticals Ireland Limited Stabili farmacinė kompozicija ir jos panaudojimo būdai
ES2856959T3 (es) 2009-06-15 2021-09-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (fr) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
US20150004224A1 (en) 2012-01-06 2015-01-01 Omthera Phrmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
KR20150028233A (ko) 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-３ 지방산의 조성물
DK3363433T3 (da) 2012-06-29 2021-03-08 Amarin Pharmaceuticals Ie Ltd Fremgangsmåder til reduktion af risikoen for en kardiovaskulær begivenhed i et individ i statinbehandling ved anvendelse af eicosapentaensyreetylester
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3135279A4 (fr) * 2014-04-25 2018-01-03 Yamada Bee Company, Inc. Accélérateur d'absorption d'acide gras insaturé
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
PT4056176T (pt) 2018-09-24 2024-05-27 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de eventos cardiovasculares num indivíduo
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition

Also Published As

Publication number Publication date
WO1990004391A1 (fr) 1990-05-03
AU4485689A (en) 1990-05-14
GB2223943A (en) 1990-04-25
GB8824709D0 (en) 1988-11-30

Similar Documents

Publication Publication Date Title
CA2000881A1 (fr) Forme posologique orale d'acides omega-3 polyinsatures
JP5829607B2 (ja) ω３脂肪酸の配合製剤
ES2826201T3 (es) Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados
CA2577345C (fr) Preparation pour gelee alimentaire
CA2432020C (fr) Produits de coenzyme q possedant des qualites de dissolution elevees
JP4592681B2 (ja) 疎水性栄養素の安定なビーズ
CA2742227C (fr) L'utilisation de compositions d'acide gras comme laxatifs
MX2013001190A (es) Composiciones farmaceuticas y/o dieteticas con base en acidos grasos de cadena corta.
JP2010116414A (ja) 心血管事象を予防するための必須脂肪酸
JPH04342525A (ja) ホスホリパーゼａ２抑制用薬剤の製造方法
CN102209534A (zh) 包封含脂肪酸油乳剂的多糖胶囊
IE832358L (en) Compositions comprising a pyrimidopyrimidine derivative
JP2010159276A6 (ja) 疎水性栄養素の安定なビーズ
EA012371B1 (ru) Фармацевтическая композиция, содержащая микрокапсулы статинов, суспендированные в алкиловых эфирах полиненасыщенных жирных кислот (pufa )
JP2009541433A (ja) オメガポリエン脂肪酸の経口投与のための医薬品の組成物、及び１又はそれ以上の配合禁忌の有効成分、並びにその調剤の工程
WO2019008101A1 (fr) Forme posologique solide à enrobage entérique comprenant des sels d'acides aminés d'acides gras oméga-3
JPH0761954B2 (ja) コレステロール低下または上昇抑制剤
US20130224304A1 (en) Effervescent nutritional and/or dietary supplement composition
CA2335713C (fr) Forme posologique par voie orale
MXPA04008151A (es) Capsulas de envoltura dura que contienen ibuprofeno.
WO2013072767A1 (fr) Compositions et préconcentrés comprenant au moins un salicylate et un mélange huileux d'acide gras oméga-3
JPS6024767B2 (ja) 腸溶性硬カプセル剤
EP2753305A1 (fr) Suppositoires enrobés
US9314435B2 (en) Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules
JP3640005B2 (ja) ソフトカプセル用皮膜

Legal Events

Date Code Title Description
FZDE Dead